CN110679813A - 一种用于减重的益生菌保健饮料 - Google Patents
一种用于减重的益生菌保健饮料 Download PDFInfo
- Publication number
- CN110679813A CN110679813A CN201911105853.0A CN201911105853A CN110679813A CN 110679813 A CN110679813 A CN 110679813A CN 201911105853 A CN201911105853 A CN 201911105853A CN 110679813 A CN110679813 A CN 110679813A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- probiotic
- mixed
- lactobacillus
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 63
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 63
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 46
- 235000013361 beverage Nutrition 0.000 title claims abstract description 20
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 17
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 17
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 17
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 15
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 15
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 15
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 15
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 14
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 14
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 11
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 11
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 11
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 3
- 230000036541 health Effects 0.000 claims description 26
- 241000894006 Bacteria Species 0.000 claims description 17
- 230000004580 weight loss Effects 0.000 claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 20
- 230000009286 beneficial effect Effects 0.000 abstract description 12
- 241000186000 Bifidobacterium Species 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 2
- 150000004675 formic acid derivatives Chemical class 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000007366 host health Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/84—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter using microorganisms or biological material, e.g. enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供一种用于减重的益生菌保健饮料，包括混合益生菌和MCT，所述混合益生菌由格式乳杆菌LG08、两歧双歧杆菌、鼠李糖乳杆菌LRa05、植物乳杆菌Lp90、植物乳杆菌CW006、乳双歧杆菌组成，其质量百分比为10‑33%长双歧杆菌BL21、5‑20%两歧双歧杆菌、5‑27%嗜酸乳杆菌、10‑47%植物乳杆菌Lp90、5‑23%乳双歧杆菌。本发明以改善肥胖者的肠道菌群结构为思路，通过改善肠道菌群结构，达到显著的减重效果，有利于肥胖人群张弛有度，不产生心理抗拒，也不产生心理和生理依赖，避免减肥过程中常见的反弹。
Description
技术领域
本发明属于益生菌保健品技术领域，具体涉及一种用于减重的益生菌保健饮料。
背景技术
近二十年来，随着人类对微生物菌群研究的深入，已经认识到人体肠道菌群与人体健康有着密不可分的关系。人体被视为一个“超级生物体”，人体内的微生物的数量约是人的细胞数量十倍，而微生物的基因组则约为人基因组的100倍。这些微生物与人体共同进化，两者的生存与代谢紧密相关。肠道菌群对人的健康至关重要。很多慢性疾病都与肠道菌群相关，如肥胖、糖尿病、结肠癌等。在这些肥胖人群中，肠道菌群结构与健康人群的相比有明显的差异，而通过饮食或药物的方式对肥胖人群进行有效的干预，使其体质指数有明显下降，肠道菌群也会发生明显的改变，表现为有益菌增加，有害菌下降。因此以肠道菌群为靶点的饮食干预作为新型减肥方式引起了学术界的关注。
人的健康受肠道菌群、宿主及环境的相互作用影响。肠道菌群与宿主的遗传及环境相互作用进而影响宿主的健康。一方面肠道菌群能够释放毒素（如脂多糖）或有益的代谢物（如维生素和短链脂肪酸）来损伤或造福宿主，另一方面宿主的遗传通过先天免疫与营养的可获得性对肠道菌群施加选择性压力，而饮食对肠道菌群结构与功能的塑造比宿主的遗传具有更大的潜力，进而影响宿主的健康状态。
联合国粮农组织世界卫生组织联合专家组定义益生菌是适量服用后，对宿主健康有益的活的微生物，它有利于有益微生物的生长，抑制有害菌的生长，能够维持宿主肠道菌群各成员的平衡。益生菌有以下几个特点：有益于宿主健康；无毒无致病性；对胃酸及胆盐具有一定的耐受性；可在消化道中存活；能定植在肠道中；能够产生对宿主消化吸收有用的代谢物；加工过程不易失活，贮存简便；感官性良好。然而，如果对不同的有益菌进行适当的配比，以及研制出有利于有益菌生长的益生性营养素的配比，是极具挑战性的工作。本发明就是基于这种肠道菌群与肥胖之间的关系，经过长期研究，筛选出的一种益生菌保健饮料，，达到显著的减肥减重效果。
发明内容
针对现有技术中的不足之处，本发明提供一种用于减重的益生菌保健饮料。
为了达到上述目的，本发明技术方案如下：
一种用于减重的益生菌保健饮料，包括混合益生菌和MCT，所述混合益生菌由格式乳杆菌LG08、两歧双歧杆菌、鼠李糖乳杆菌LRa05、植物乳杆菌Lp90、植物乳杆菌CW006、乳双歧杆菌组成，其质量百分比为10-33%长双歧杆菌BL21、5-20%两歧双歧杆菌、5-27%嗜酸乳杆菌、10-47%植物乳杆菌Lp90、5-23%乳双歧杆菌。
进一步的，所述混合益生菌中各组成菌群的质量百分比为23%长双歧杆菌BL21、10%两歧双歧杆菌、17%嗜酸乳杆菌、37%植物乳杆菌Lp90、13%乳双歧杆菌。
进一步的，所述混合益生菌活菌量为（2~3）×1010 CFU/g。
进一步的，所述混合益生菌和MCT的质量比为（0.75 - 1）:10。作为优选，质量比为0.8167:10。
进一步的，所述益生菌保健饮料每10mL中含有10gMCT。
本发明的原料：
（1）长双歧杆菌：长双歧杆菌属于双歧杆菌属中的一种细菌：长双歧杆菌取自健康人体肠道，筛选出完全适合人体之菌株，是对人体有益的一种菌种；使用于一般食品类的长双歧杆菌，具有调节肠道健康的功效；
（2）两歧双歧杆菌：两岐双歧杆菌在人体肠内发酵后可产生乳酸和醋酸，能提高钙、磷、铁的利用率，促进铁和维生素D的吸收。双歧杆菌发酵乳糖产生半乳糖，是构成脑神经系统中脑苷脂的成分，与婴儿出生后脑的迅速生长有密切关系。双歧杆菌可以产生维生素B1、B2、B6、B12及丙氨酸、缬氨酸、天冬氨酸和苏氨酸等人体必需的营养物质；
（3）嗜酸乳杆菌：具有降血压；促进钙铁吸收；调整肠道菌群；抑制癌细胞增殖；增强免疫力；改善睡眠；抗氧化等作用；
（4）植物乳杆菌：具有很多的保健作用，如：有一定的免疫调节作用；对致病菌有抑制作用；降低血清胆固醇含量和预防心血管疾病；维持肠道内菌群平衡；促进营养物质吸收；缓解乳糖不耐症；抑制肿瘤细胞的形成等；
（5）乳双歧杆菌：可以通过调整肠道菌群，并通过产生乙酸、乳酸等短链脂肪酸来抑制肠道腐败菌的生长和有毒代谢产物的形成，刺激肠蠕动，从而减少水分的过度吸收而缓解便秘症状；可通过调整肠道正常菌群，抑制肠道许多腐败菌生长，从而减少一些肠源性致癌物的产生；
（6）MCT：是中链甘油三酯（Medium Chain Triglycerides）的简称，是由碳链长度6-12的饱和中链脂肪酸组成的甘油三酯。医药行业中常用作溶剂、载体和乳化剂，也可以作为食品行业中香精、色素和维生素的溶剂，其具有不易被胃酸分解，易在肠道中水解的特性。天然存在于棕榈仁油、椰子油等食品和母乳中，是膳食脂肪的来源之一。作为食品添加剂，中链甘油三酯仅由饱和脂肪酸构成，凝固点低，室温下为液体，粘度小。与大豆油比较，完全是无臭、无色的透明液体。与普通的油脂和氢化油脂相比，中链甘油三酯不饱和脂肪酸的含量极低，氧化稳定性非常好，其碘值不超过0.5，MCT在高温和低温下特别稳定。
有益效果：本发明以改善肥胖者的肠道菌群结构为思路，通过改善肠道菌群结构，达到显著的减重效果，有利于肥胖人群张弛有度，不产生心理抗拒，也不产生心理和生理依赖，避免减肥过程中常见的反弹。
具体实施方式
以下参照具体的实施例来说明本发明。本领域技术人员能够理解，这些实施例仅用于说明本发明，其不以任何方式限制本发明的范围。
实施例1
一种用于减重的益生菌保健饮料，每10mL的益生菌保健饮料中含有10gMCT和0.8167g混合益生菌；混合益生菌由23%长双歧杆菌BL21、10%两歧双歧杆菌、17%嗜酸乳杆菌、37%植物乳杆菌Lp90、13%乳双歧杆菌组成，混合益生菌活菌量为3×1010 CFU/g。
实施例2
一种用于减重的益生菌保健饮料，每10mL的益生菌保健饮料中含有10gMCT和0.8167g混合益生菌；混合益生菌由10%长双歧杆菌BL21、5%两歧双歧杆菌、27%嗜酸乳杆菌、35%植物乳杆菌Lp90、23%乳双歧杆菌组成，混合益生菌活菌量为2×1010 CFU/g。
实施例3
一种用于减重的益生菌保健饮料，每10mL的益生菌保健饮料中含有10gMCT和0.8167g混合益生菌；混合益生菌由33%长双歧杆菌BL21、20%两歧双歧杆菌、10%嗜酸乳杆菌、27%植物乳杆菌Lp90、10%乳双歧杆菌组成，混合益生菌活菌量为2.8×1010 CFU/g。
实施例4
一种用于减重的益生菌保健饮料，每10mL的益生菌保健饮料中含有10gMCT和0.8167g混合益生菌；混合益生菌由30%长双歧杆菌BL21、13%两歧双歧杆菌、5%嗜酸乳杆菌、47%植物乳杆菌Lp90、5%乳双歧杆菌组成，混合益生菌活菌量为2.4×1010 CFU/g。
实施例5
一种用于减重的益生菌保健饮料，每10mL的益生菌保健饮料中含有10gMCT和0.8167g混合益生菌；混合益生菌由25%长双歧杆菌BL21、20%两歧双歧杆菌、25%嗜酸乳杆菌、10%植物乳杆菌Lp90、20%乳双歧杆菌组成，混合益生菌活菌量为2.6×1010 CFU/g。
实验验证
以小鼠为实验对象，构建肥胖小鼠模型，研究益生菌保健饮料对肥胖小鼠的影响。具体方法参照保健食品检验与评价技术规范(2003版)。
1）选实验小白鼠，每组10只，标准条件饲养，供水。适应性饲养1周后，分组进行保护性处理。根据分组，用高脂饲料饲喂造成肥胖模型，体重30克左右。随机分组，进行实施例1至5的受试样品（益生菌保健饮料）的灌胃，和用中计量的生理盐水灌胃的阳性对照组；用受试样品给予时间30d，观察测试四周。另外设立对照组：以相同计量的生理盐水灌胃。灌胃计量0.8ml，每天2次。每周进行各组小鼠重量测量，结果见表1。
表1每周进行各组小鼠平均重量
| 组别 | 初始体重/克 | 一周体重/克 | 二周体重/克 | 三周体重/克 | 四周体重/克 |
| 实施例1 | 30.2 | 32.5 | 32.3 | 31 | 30.0 |
| 实施例2 | 30.5 | 32.8 | 33 | 31.8 | 30.2 |
| 实施例3 | 30.3 | 33.0 | 34.1 | 32.5 | 31 |
| 实施例4 | 29.8 | 33.5 | 34.5 | 32.4 | 30.7 |
| 实施例5 | 30 | 33.8 | 34.4 | 32.2 | 30.4 |
| 对照组 | 30 | 35 | 41 | 47 | 56 |
由上表1可知，随着饲养时间延长，各组小鼠重量均呈现增长趋势，但不同组的增长速度不同。与对照组，实验组均能不同程度延缓小鼠重量增长速度；第四周时，实验组使得小鼠重量明显回落。
2）小鼠内脏指数变化、脂体比及抗疲劳能力
在实验期满1个月后进行模拟游泳测试，测定抗疲劳能力；再进行小鼠剖杀，测定小鼠体脂比、内脏指数及抗疲劳能力，结果见表2。
由上表2可知，（1）与对照组相比，实施例1至5的内脏指数均有不同程度降低；肝脏指数和脾脏指数有所降低；脾脏指数降低极显著。（2）实施例1至5的的脂体比降低均非常显著。（3）各组小鼠的游泳时间明显不同，其中对照组时间最短，说明在减重的同时还可以增强小鼠体力。
根据动物实验验证结果，说明本发明的蛋白益生菌复合食品具有显著的减肥功效。
Claims (6)
1.一种用于减重的益生菌保健饮料，其特征在于：包括混合益生菌和MCT，所述混合益生菌由格式乳杆菌LG08、两歧双歧杆菌、鼠李糖乳杆菌LRa05、植物乳杆菌Lp90、植物乳杆菌CW006、乳双歧杆菌组成，其质量百分比为10-33%长双歧杆菌BL21、5-20%两歧双歧杆菌、5-27%嗜酸乳杆菌、10-47%植物乳杆菌Lp90、5-23%乳双歧杆菌。
2.如权利要求1所述的用于减重的益生菌保健饮料，其特征在于，所述混合益生菌中各组成菌群的质量百分比为23%长双歧杆菌BL21、10%两歧双歧杆菌、17%嗜酸乳杆菌、37%植物乳杆菌Lp90、13%乳双歧杆菌。
3. 如权利要求1所述的用于减重的益生菌保健饮料，其特征在于，所述混合益生菌活菌量为（2~3）×1010 CFU/g。
4. 如权利要求1所述的用于减重的益生菌保健饮料，其特征在于，所述混合益生菌和MCT的质量比为（0.75 - 1）:10。
5.如权利要求4所述的用于减重的益生菌保健饮料，其特征在于，所述混合益生菌和MCT的质量比为0.8167:10。
6.如权利要求1所述的用于减重的益生菌保健饮料，其特征在于，所述益生菌保健饮料每10mL中含有10gMCT。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911105853.0A CN110679813A (zh) | 2019-11-13 | 2019-11-13 | 一种用于减重的益生菌保健饮料 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911105853.0A CN110679813A (zh) | 2019-11-13 | 2019-11-13 | 一种用于减重的益生菌保健饮料 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110679813A true CN110679813A (zh) | 2020-01-14 |
Family
ID=69116505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911105853.0A Pending CN110679813A (zh) | 2019-11-13 | 2019-11-13 | 一种用于减重的益生菌保健饮料 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110679813A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111213885A (zh) * | 2020-01-20 | 2020-06-02 | 齐海心 | 一种具有调节血脂功效的益生菌组合物及其制备方法与应用 |
| CN111587952A (zh) * | 2020-05-27 | 2020-08-28 | 佛山科学技术学院 | 一种降低家犬体脂沉积的益生菌添加剂 |
| CN111700123A (zh) * | 2020-06-24 | 2020-09-25 | 广州彤博士健康科技有限公司 | 一种含有中链甘油三酯的高油酸葵花籽油配方及其制备方法 |
| CN112314943A (zh) * | 2020-10-14 | 2021-02-05 | 新食代布丁(上海)智能科技有限公司 | 一种利于减肥的复合益生菌饮品及其制备方法 |
| CN112931743A (zh) * | 2021-04-12 | 2021-06-11 | 南京乔康生物科技有限公司 | 一种有助于塑身的固体饮料及其制备方法 |
| CN113207960A (zh) * | 2020-08-31 | 2021-08-06 | 内蒙古蒙牛乳业（集团）股份有限公司 | 改善肥胖的乳双歧杆菌MN-Gup发酵乳及制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109223833A (zh) * | 2017-07-10 | 2019-01-18 | 上海立龙生物科技有限公司 | 一种预防和改善肥胖的益生菌组合物 |
-
2019
- 2019-11-13 CN CN201911105853.0A patent/CN110679813A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109223833A (zh) * | 2017-07-10 | 2019-01-18 | 上海立龙生物科技有限公司 | 一种预防和改善肥胖的益生菌组合物 |
Non-Patent Citations (5)
| Title |
|---|
| 一眼知秋: "美乐家熊宝宝乳酸菌粉", 《微信HTTPS://MP.WEIXIN.QQ.COM/S?SRC=3&TIMESTAMP=1637493017&VER=1&SIGNATURE=RSRDL5C1HNZIZAGHSCVYQRGH*GJ1ISYQ500WQJBVIAWDMSTSQQ3AXF7OAZC7-Y2K6OKKJ9SGTC01VBGGKWPSR8T1LGT-C6Y*V4C044NMVLS335GD0HHQYIMY9EFZCIYRPNC4*KKJ*ZQMWNG*O9WECG==》 * |
| 吴映蓉编: "《瘦不了的错误——营养学博士教你健康减肥不反弹》", 30 September 2011, 生活•读书•新知三联书店 * |
| 方曙光: "干货‘2019生物发酵与营养健康•益生制品产业发展高峰论坛’专题报告：益生菌与慢性疾病健康管理", 《微康益生菌HTTPS://MP.WEIXIN.QQ.COM/S/UECPZORHYU6O-F9EJKQD9Q》 * |
| 李平等: "MIX-G200复合益生菌粉的润肠通便作用", 《中国微生态学杂志》 * |
| 梅奥营养（广西）卢绍欣: "梅奥MAYO营养滴剂系列简介", 《美篇HTTPS://WWW.MEIPIAN.CN/2EQIT8FF》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111213885A (zh) * | 2020-01-20 | 2020-06-02 | 齐海心 | 一种具有调节血脂功效的益生菌组合物及其制备方法与应用 |
| CN111587952A (zh) * | 2020-05-27 | 2020-08-28 | 佛山科学技术学院 | 一种降低家犬体脂沉积的益生菌添加剂 |
| CN111700123A (zh) * | 2020-06-24 | 2020-09-25 | 广州彤博士健康科技有限公司 | 一种含有中链甘油三酯的高油酸葵花籽油配方及其制备方法 |
| CN113207960A (zh) * | 2020-08-31 | 2021-08-06 | 内蒙古蒙牛乳业（集团）股份有限公司 | 改善肥胖的乳双歧杆菌MN-Gup发酵乳及制备方法 |
| CN113207960B (zh) * | 2020-08-31 | 2023-02-28 | 内蒙古蒙牛乳业（集团）股份有限公司 | 改善肥胖的乳双歧杆菌MN-Gup发酵乳及制备方法 |
| CN112314943A (zh) * | 2020-10-14 | 2021-02-05 | 新食代布丁(上海)智能科技有限公司 | 一种利于减肥的复合益生菌饮品及其制备方法 |
| CN112931743A (zh) * | 2021-04-12 | 2021-06-11 | 南京乔康生物科技有限公司 | 一种有助于塑身的固体饮料及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beheshtipour et al. | Supplementation of Spirulina platensis and Chlorella vulgaris algae into probiotic fermented milks | |
| CN110679813A (zh) | 一种用于减重的益生菌保健饮料 | |
| CN111728111B (zh) | 一种缓解焦虑或抑郁的益生菌组合物及其应用 | |
| Linares et al. | Lactic acid bacteria and bifidobacteria with potential to design natural biofunctional health-promoting dairy foods | |
| CN108244252A (zh) | 益生菌多元蛋白粉及其制备方法 | |
| CN115074274B (zh) | 含乳酸菌的组合物及其用途 | |
| WO2010003790A1 (en) | A nutritional composition with free amino acids and structured lipids | |
| CN103271274B (zh) | 一种营养保健粥 | |
| CN114250179A (zh) | 一种具有减肥功效的微生物组合及其应用 | |
| CN112790250A (zh) | 促进肠道健康的婴儿配方奶粉及其制备方法 | |
| WO2020240595A1 (en) | Nutritional compositions, food and beverage compositions containing enhanced nutritional content | |
| CN108243603A (zh) | 使用长双歧杆菌调节情绪反应性并治疗或预防亚临床心境紊乱的方法和组合物 | |
| Pramanik et al. | A systematic review on selection characterization and implementation of probiotics in human health | |
| Astashkina et al. | Microbiological quality control of probiotic products | |
| CN110771766A (zh) | 用于儿童肠绞痛、腹泻、修复肠道的益生菌保健饮料 | |
| Shazly et al. | Probiotic Yoghurt made from milk of ewes fed a diet supplemented with Spirulina platensis or fish oil | |
| Attri et al. | Probiotics and their potential applications: an introduction | |
| Istrati et al. | Fermented functional beverages | |
| US9826766B2 (en) | Use of polysaccharides for the intestinal well-being of nursing infants and/or infants | |
| CN116671569A (zh) | 一种活性益生菌抗氧化软糖及其制备方法 | |
| WO2020176624A1 (en) | Probiotics and probiotic compositions having modified carbohydrate metabolism | |
| Kushwaha et al. | Probiotics and the physiological & biological aspects of probiotic microorganisms | |
| Bhatt et al. | Probiotic: An uprising human health concept | |
| Kumar et al. | Health-promoting probiotic functional foods | |
| Georgieva et al. | Probiotics: past, present, and future challenges |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200114 |
|
| RJ01 | Rejection of invention patent application after publication |